MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
MBX Biosciences (Nasdaq: MBX) has announced it will release topline results from its Phase 2 clinical trial of canvuparatide, a potential once-weekly treatment for chronic hypoparathyroidism (HP). The company will host an investor webcast and conference call on Monday, September 22 at 8 AM ET to discuss the Avail™ Phase 2 trial results.
Investors can access the presentation through a live webcast or by dialing 1-877-407-0779 (US) or 1-201-389-0914 (international). The webcast and slide presentation will be available on the company's investor relations website.
MBX Biosciences (Nasdaq: MBX) ha annunciato che renderà disponibili i risultati principali dello studio clinico di fase 2 di canvuparatide, potenziale trattamento settimanale per l'ipoparatiroidismo cronico (HP). L'azienda terrà un webcast per investitori e una conference call lunedì 22 settembre alle 8:00 ET per discutere i risultati dello studio Avail™ di Fase 2. Gli investitori potranno accedere alla presentazione tramite webcast in diretta o chiamando 1-877-407-0779 (US) o 1-201-389-0914 (internazionale). Il webcast e la presentazione saranno disponibili sul sito di relazioni con gli investitori dell'azienda.
MBX Biosciences (Nasdaq: MBX) ha anunciado que publicará los resultados principales de su ensayo clínico de fase 2 de canvuparatide, un posible tratamiento semanal para la hipoparatiroidismo crónico (HP). La empresa organizará un webcast para inversores y una llamada de conferencias el lunes 22 de septiembre a las 8:00 ET para comentar los resultados del ensayo Avail™ de Fase 2. Los inversores pueden acceder a la presentación vía webcast en vivo o llamando al 1-877-407-0779 (EE. UU.) o al 1-201-389-0914 (internacional). El webcast y la presentación estarán disponibles en el sitio web de relaciones con inversores de la empresa.
MBX Biosciences(나스닥: MBX)는 칸부파라이드(canvuparatide)의 2상 임상시험의 주요 결과를 발표할 예정이며, 만성 저칼슘혈증(HP)에 대한 주 1회 치료제 후보가 될 수 있습니다. 회사는 Avail™ 2상 시험 결과를 논의하기 위해 9월 22일 월요일 동부시간 8:00에 투자자 웹캐스트와 컨퍼런스 콜을 개최합니다. 투자자들은 생방송 웹캐스트를 통해서나 전화번호 1-877-407-0779(미국) 또는 1-201-389-0914(국제)로 접속할 수 있습니다. 웹캐스트와 슬라이드 프리젠테이션은 회사의 투자자 관계 웹사이트에서 제공됩니다.
MBX Biosciences (Nasdaq : MBX) a annoncé qu'elle publiera les résultats principaux de son essai clinique de phase 2 de canvuparatide, une éventuelle thérapie hebdomadaire pour l'hypoparathyroïdie chronique (HP). La société organisera un webcast pour investisseurs et une conférence téléphonique lundi 22 septembre à 8 h (ET) pour discuter des résultats de l'essai Avail™ de phase 2. Les investisseurs pourront accéder à la présentation via le webcast en direct ou en composant le 1-877-407-0779 (États‑Unis) ou le 1-201-389-0914 (international). Le webcast et la présentation seront disponibles sur le site des relations investisseurs de l'entreprise.
MBX Biosciences (Nasdaq: MBX) hat bekannt gegeben, dass sie die Endergebnisse aus der Phase-2-Studie von Canvuparatide, einer potenziellen wöchentlichen Behandlung für chronischen Hypoparathyreoidismus (HP), veröffentlichen wird. Das Unternehmen wird eine Investoren-Webcast-Veranstaltung und eine Telefonkonferenz am Montag, 22. September, um 8 Uhr ET abhalten, um die Avail™-Phase-2-Studienergebnisse zu besprechen. Investoren können die Präsentation über einen Live-Webcast oder unter den Nummern 1-877-407-0779 (USA) oder 1-201-389-0914 (international) erreichen. Der Webcast und die Folienpräsentation werden auf der Investor Relations-Website des Unternehmens verfügbar sein.
أعلنت MBX Biosciences (المدرجة في ناسداك: MBX) أنها ستصدر النتائج الرئيسية من تجربتها الإكلينيكية من المرحلة الثانية لـ canvuparatide، وهو علاج محتمل أسبوعياً لـ قصور جارات الدرقية المزمن (HP). ستعقد الشركة وبثاً للمستثمرين ومكالمة مؤتمر يوم الإثنين 22 سبتمبر الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة لمناقشة نتائج تجربة Avail™ من المرحلة 2. يمكن للمستثمرين الوصول إلى العرض عبر بث مباشر أو بالاتصال على 1-877-407-0779 (الولايات المتحدة) أو 1-201-389-0914 (دولي). سيكون البث المباشر وعرض الشرائح متاحين على موقع علاقات المستثمرين بالشركة.
MBX Biosciences（纳斯达克股票代码：MBX）宣布将公布其< b>阶段2临床试验的初步结果，关于canvuparatide，这是一种可能的每周治疗方案，用于慢性甲状旁腺功能低下症（HP）。公司将于美国东部时间周一 9 月 22 日 8:00举行投资者网络直播和电话会议，讨论Avail™阶段2试验的结果。投资者可通过现场网络直播或拨打1-877-407-0779（美国）或1-201-389-0914（国际）接入。网络直播和幻灯片将在公司的投资者关系网站上提供。
- None.
- None.
CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) and host an investor webcast on Monday, September 22.
The Company will host a conference call and webcast at 8 am ET on Monday, September 22 to discuss the results from the Avail™ Phase 2 trial. Those who would like to participate may access the live webcast here or dial 1-877-407-0779 (US) or 1-201-389-0914 (international). The live and archived webcast of the call and slide presentation will be available in the Investors section of the Company’s website at https://investors.mbxbio.com/news-events/events.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.
Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
IECommsMBX@inizioevoke.com
(937) 232-4889
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
When will MBX Biosciences announce the Phase 2 trial results for canvuparatide?
What is the purpose of MBX Biosciences' canvuparatide clinical trial?
How can investors access MBX Biosciences' Phase 2 trial results presentation?
What type of company is MBX Biosciences (Nasdaq: MBX)?
